Endocrinology

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Type 2 diabetes and prediabetes were associated with accelerated brain aging, particularly among men and persons with poor cardiometabolic health, according to new research.

In a study of adolescents with obesity, symptoms of depression and eating disorders decreased over the course of a 52-week intensive behavioral intervention.

Vials of tirzepatide 2.5 mg and 5 mg will be available with a prescription for the labeled drug through LillyDirect after completing a multistep verification process, the company said.

The Omnipod 5 is now the first automated insulin delivery system available for both T1D and T2D in the US.

Results of a global analysis of over 30 million cases showed significantly higher odds for suicidal ideation among adults who received semaglutide vs other medications.

Your daily dose of the clinical news you may have missed.

Anila Chadha, MD, talks to Patient Care about how antiobesity medications can aid in reducing CVD risk in patients with obesity.

Results of the 3-year SURMOUNT-1 study reflect the longest trial to date of tirzepatide in adults with overweight/obesity and risk for developing T2D.

Younger US veterans with PTSD and type 2 diabetes who no longer met criteria for PTSD were less likely to initiate insulin and had reduced odds of mortality.

Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.

Primary care clinicians can screen at-risk individuals for type 1 diabetes with a single autoantibody panel. It pays to test and educate early, according to this author.

No health system across the 28 analyzed in this study demonstrated appropriate SGLT2i prescribing for more than 25% of eligible individuals.

Your daily dose of the clinical news you may have missed.

Incretin analogues, an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are in the new mix.

In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.

Your daily dose of the clinical news you may have missed.

Finerenone treatment achieved a statistically significant reduction in a composite endpoint of CV death and HF events in a population not limited to CKD in T2D, Bayer announced.

New study findings suggest that in older adults stable HbA1c within individualized target ranges over time may help reduce risk of Alzheimer disease and other dementias.

Caissa Troutman, MD, discusses how clinicians can tailor management plans to reduce risk of developing T2D in patients with obesity.

Tirzepatide reduced the risk of severe heart failure outcomes by 38% and drove weight loss of 15.7% in adults with HFpEF and obesity, with and without T2D..

Lack of dosing experience and errors with converting measurement units may lead to overdosing, the agency reported.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.